Published in Lab Business Week, April 8th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at MultiCell Technologies.
Report 1: MultiCell Technologies, Inc. (MCET), a developer of drugs based on advanced immune system modulation technologies, has announced that the company's proprietary anticancer technologies eradicated cancer in animal studies and prevented the recurrence of the disease.
The research focused on a combination therapy based on MCET's MCT-465 drug candidate co-administered with IgNP, a proprietary MCET immune-modulation drug.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.